Thus, the potential of Nrf2 as the treatment target of NAFLD has been demonstrated using Nrf2 activators in vivo and in vitro (Shimozono et al., 2013). Here, NFE2L2 is linked to metabolic dysfunction-associated steatotic liver disease.